The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA
Open accessThe DOI matches its Crossref record; 24 of the 24 references it cites were found in a registry or an index.
Abstract
Obesity has become a serious public health problem that has stimulated primordial and primary prevention efforts, and a triad of management options (lifestyle, pharmacotherapy, and surgical interventions). A growing body of evidence supports the need for a multi-pronged, clinic-based approach that leverages the synergy between pharmaceutical and lifestyle modification. Recent US policy changes-namely, the passage of the Patient Protection and Affordable Care Act coupled with recognition of obesity as a disease by the American Medical Association-suggest that financial incentives and attitudes towards obesity management are changing. This paradigm shift has implications for current and future obesity pharmacotherapy. However, barriers to pharmacotherapy utilization include patient and physician perceptions of modest efficacy, historical safety issues, regulatory obstacles, and lack of reimbursement. The shifting attitudes and challenges associated not only with a multi-payer system, but also the lack of clearly defined cross-payer reimbursement strategies, prompted a survey to determine coverage for obesity treatment. Participants indicated that federal/state mandates and growth of quality-driven healthcare initiatives will eventually drive wider pharmacotherapy reimbursement within 1-5 years. There are signs that federal/state programs are already moving towards reimbursement by improving quality measures to track obesity outcomes and reduce costs. Future research on clinical and economic outcomes of combination weight-management programs coupled with innovative approaches (e.g., eHealth) in the real-world setting that demonstrate value to patients, healthcare providers, payers, and employers will help reshape obesity management by reducing barriers and broadening reimbursement coverage for anti-obesity pharmacotherapy.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin
(2002) · New England Journal of Medicine · doi:10.1056/nejmoa012512 · Cited by 19,011 · cited 1×
“Clinical trials of behavior and/or lifestyle modification have shown modest weight loss and beneficial effects on glycemic control, cardiovascular risk factors, and development of type 2 diabetes mellitus [21–26], but these findings have been difficult to translate into primary care settings for a number of reasons.”
BackgroundDiabetes Prevention Program Research Group (2009) · The Lancet · doi:10.1016/s0140-6736(09)61457-4 · Cited by 3,020 · cited 1×
“Clinical trials of behavior and/or lifestyle modification have shown modest weight loss and beneficial effects on glycemic control, cardiovascular risk factors, and development of type 2 diabetes mellitus [21–26], but these findings have been difficult to translate into primary care settings for a number of reasons.”
BackgroundJensen, M. D., Ryan, D. H., Apovian, C. M., Ard, J. D., Comuzzie, A. G., Donato, K. A., Hu, F. B., Hubbard, V. S., Jakicic, J. M., Kushner, R. F., et al. (2014) · Circulation · doi:10.1161/01.cir.0000437739.71477.ee · Cited by 2,735
Wing, R. R., Lang, W., Wadden, T. A., Safford, M., Knowler, W. C., Bertoni, A. G., Hill, J. O., Brancati, F. L., Peters, A., Wagenknecht, L., et al. (2011) · Diabetes Care · doi:10.2337/dc10-2415 · Cited by 1,828
Income, Poverty, and Health Insurance Coverage In The United States: 2006: (668082007-001)
DeNavas-Walt, C., Proctor, B. D., & Smith, J. (2007) · PsycEXTRA Dataset · doi:10.1037/e668082007-001 · Cited by 1,636
Picot, J., Jones, J., Colquitt, J., Gospodarevskaya, E., Loveman, E., Baxter, L., & Clegg, A. (2009) · Health Technology Assessment · doi:10.3310/hta13410 · Cited by 1,066 · cited 1×
“of the different surgical treatment options is beyond the scope of this paper, but bariatric surgery has the demonstrated benefits of rapid and substantial weight loss and clinically important improvements in some biomarkers of co-morbid disease [35–37].”
BackgroundPi-Sunyer, X. (2009) · Postgraduate Medicine · doi:10.3810/pgm.2009.11.2074 · Cited by 1,025
US Department of Health & Human Services; Public Health Service; Office of Surgeon General (2001) · PsycEXTRA Dataset · doi:10.1037/e301232004-001 · Cited by 1,001
Long-term Drug Treatment for Obesity: A Systematic and Clinical Review
Yanovski, S. Z., & Yanovski, J. A. (2014) · JAMA · doi:10.1001/jama.2013.281361 · Cited by 876
Primary Care Physicians’ Attitudes about Obesity and Its Treatment
Foster, G. D., Wadden, T. A., Makris, A. P., Davidson, D., Sanderson, R. S., Allison, D. B., & Kessler, A. (2003) · Obesity Research · doi:10.1038/oby.2003.161 · Cited by 744
Cited by
Progress and challenges in anti-obesity pharmacotherapy
Bessesen, D. H., & Van Gaal, L. F. (2018) · The Lancet Diabetes & Endocrinology · doi:10.1016/s2213-8587(17)30236-x · Cited by 347
Ard, J., Fitch, A., Fruh, S., & Herman, L. (2021) · Advances in Therapy · doi:10.1007/s12325-021-01710-0 · Cited by 297
Weight Bias and Stigma: Public Health Implications and Structural Solutions
Pearl, R. L. (2018) · Social Issues and Policy Review · doi:10.1111/sipr.12043 · Cited by 278
Gomez, G., & Stanford, F. C. (2018) · International Journal of Obesity · doi:10.1038/ijo.2017.287 · Cited by 128
Perceptions of barriers to effective obesity management in Canada: Results from the ACTION study
Sharma, A. M., Bélanger, A., Carson, V., Krah, J., Langlois, M., Lawlor, D., Lepage, S., Liu, A., Macklin, D. A., MacKay, N., et al. (2019) · Clinical Obesity · doi:10.1111/cob.12329 · Cited by 86
Metadata
- Authors
- Baum, C., Andino, K., Wittbrodt, E., Stewart, S., Szymanski, K., & Turpin, R.
- Venue
- PharmacoEconomics
- Published
- 2015-02-17
- Volume
- 33
- Issue
- 7
- Pages
- 643-653
- ISSN
- 1170-7690 (ISSN-L)
- 1179-2027
- OpenAlex
- W2015145324
- Cited by
- 42
- References
- 24
- FWCI
- 2.54
- Type
- journal article
- Language
- en
- Open access
- hybrid
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA. https://app.cochat.ai/papers/10.1007/s40273-015-0264-0
- The paper
- Baum, C., Andino, K., Wittbrodt, E., Stewart, S., Szymanski, K., & Turpin, R. (2015). The Challenges and Opportunities Associated with Reimbursement for Obesity Pharmacotherapy in the USA. PharmacoEconomics. https://doi.org/10.1007/s40273-015-0264-0
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.